Trial of imatinib for people with RUNX1 deficiency
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests if imatinib can help people with a genetic condition called RUNX1 deficiency, which causes bleeding problems. It aims to increase the activity of the RUNX1 gene to improve blood clotting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed RUNX1 gene mutation that causes the condition.
- You must have a history of significant bleeding problems, such as needing platelet transfusions or medication for bleeding.
- You must be at least 18 years old and have adequate organ function (kidneys, liver, blood counts).
- You must not have certain cancer treatments or medications that affect platelets, and you must not be pregnant.
- You must agree to use effective birth control during the study and for 30 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a stem cell transplant from a half-matched donor can treat blood cancers in people with a RUNX1 gene mutation. The goal is to replace the faulty bone marrow with healthy cells that can fight the cancer.
This study follows people who have a known or suspected RUNX1 gene variant linked to FPDMM-like features. It may help improve understanding of the gene, and participants may contribute samples that researchers use for genetic testing and research.
This trial tests a drug called pacritinib in people with myelodysplastic syndromes (MDS) or MDS/myeloproliferative neoplasms (MDS/MPN). The drug targets several proteins that may help control the disease, especially for those who have not responded to other treatments.
This trial tests a combination of two drugs, momelotinib and a hypomethylating agent, for people with certain slow-growing blood cancers. If you have a diagnosis like chronic myelomonocytic leukemia or chronic neutrophilic leukemia and have an enlarged spleen, this study might be exploring a new treatment option for you.
This trial studies people with advanced or metastatic gastrointestinal stromal tumor (GIST) who have been on the drug imatinib for 10 years with stable, non-growing disease. The goal is to see how effective it is to keep imatinib going after this long period.
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
Hear when a new Inherited Bone Marrow Failure Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.